HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
about
Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsMolecular pathways: HER3 targeted therapyThe brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care Syst
P2860
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@en
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@nl
type
label
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@en
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@nl
prefLabel
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@en
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@nl
P2093
P2860
P1433
P1476
HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.
@en
P2093
Anil A Joy
Christine Brezden-Masley
Daniel Rayson
Deanna McLeod
Jean-François Boileau
Karen A Gelmon
Sunil Verma
P2860
P304
P356
10.1634/THEONCOLOGIST.2013-0217
P577
2013-11-08T00:00:00Z